Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

NCT05998642 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

NETWORK

Sponsor class

Conditions

Non-hodgkin Lymphoma

Interventions

DRUG: Methotrexate
DRUG: Rituximab (where available)
DRUG: Ibrutinib

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]